PROTECT YOUR DNA WITH QUANTUM TECHNOLOGY
Orgo-Life the new way to the future Advertising by AdpathwayA comprehensive network meta-analysis evaluating non-invasive brain stimulation techniques has found that distinct stimulation modalities and cortical targets yield outcome-specific improvements for chronic musculoskeletal pain and its frequent psychiatric comorbidities. Synthesizing data from fifty randomized controlled trials encompassing 2,203 human participants, investigators examined how repetitive transcranial magnetic stimulation, transcranial direct current stimulation, cranial electrotherapy stimulation, and related modalities altered pain intensity, anxiety, and depression. The empirical synthesis demonstrated that low-frequency repetitive transcranial magnetic stimulation applied over the dorsolateral prefrontal cortex achieved the foremost ranking for pain alleviation in the overall chronic musculoskeletal pain cohort, while transcranial random noise stimulation directed at the primary motor cortex and intermittent theta-burst stimulation over the dorsolateral prefrontal cortex ranked highest for anxiety and depression reductions, respectively. Because chronic pain syndromes frequently disrupt affective regulation alongside physical function, these comparative findings provide structured comparative evidence regarding which non-invasive modalities most effectively address specific sensory and emotional manifestations across clinical populations.
Chronic musculoskeletal pain represents persistent or recurring discomfort arising from pathological processes that directly compromise bones, joints, muscles, or associated soft tissues, currently impacting between twenty and thirty percent of the global population as the second leading contributor to nonfatal disability worldwide. In routine clinical care, pharmacological approaches such as acetaminophen and nonsteroidal anti-inflammatory agents serve as primary therapeutic options, yet prolonged pharmacotherapy and particularly opioid administration carry substantial risks of adverse reactions, gastrointestinal injury, and chemical dependency. Non-pharmacological treatments including physical exercise and cognitive behavioral therapy provide valuable safety profiles, but their therapeutic outcomes remain variable across patient groups. Non-invasive brain stimulation modalities have consequently emerged as promising therapeutic strategies designed to alter cortical excitability, reorganize disordered neural pain networks, and attenuate central sensitization. Despite growing interest, previous clinical trials have predominantly featured modest sample cohorts, heterogeneous stimulation parameters, and an absence of direct comparative trials, leaving the relative clinical efficacy of competing stimulation protocols unresolved across individual symptom domains.
To rigorously evaluate these therapeutic modalities, the researchers performed an extensive systematic literature search across seven primary biomedical databases—comprising PubMed, Web of Science, Embase, the Cochrane Library, MEDLINE, PsycINFO, and CINAHL—covering records from database inception through October 7, 2025. The investigators restricted eligibility exclusively to English-language randomized controlled trials conducted in adult human participants presenting with chronic musculoskeletal pain enduring for a minimum duration of three months. Included investigations were required to compare active non-invasive brain stimulation protocols against sham procedures or alternative active comparators while reporting validated psychometric outcome measures. Pain intensity was evaluated via Visual Analogue Scales or Numerical Rating Scales, anxiety was assessed using standardized instruments such as the Hamilton Anxiety Rating Scale, Beck Anxiety Inventory, or the Hospital Anxiety and Depression Scale, and depression was gauged using the Hamilton Depression Rating Scale, Beck Depression Inventory, or Hospital Anxiety and Depression Scale. Studies examining ineligible cohorts, such as healthy volunteers, acute pain sufferers, or individuals presenting primary headaches or neuropathic, visceral, or cancer pain, were systematically excluded.
The methodological framework applied a frequentist network meta-analysis using Stata version 17.0, enabling the simultaneous integration of direct trial comparisons and indirect mathematical inferences across interventions that had not been tested head-to-head. Treatment effects across continuous metrics were quantified using standardized mean differences alongside ninety-five percent confidence intervals, with mean differences applied when identical assessment scales were pooled across investigations. The underlying consistency between direct and indirect trial evidence was verified globally using design-by-treatment interaction models and evaluated locally via node-splitting techniques and loop-specific assessments, confirming no statistically significant global inconsistency for pain, anxiety, or depression models. Relative intervention hierarchies were derived using the surface under the cumulative ranking curve, which establishes the statistical probability that an intervention ranks among the most effective options. Methodological rigor was systematically evaluated using the Cochrane Risk of Bias 2.0 tool, which categorized fifteen trials as possessing low risk of bias, twenty-three exhibiting some concerns, and twelve presenting high risk of bias, largely stemming from inadequate randomization documentation, statistical handling of missing data, or incomplete trial reporting.
Across the fifty included trials, participant ages averaged between 31 and 75 years, with female individuals constituting approximately eighty-two percent of the pooled clinical population. Specific diagnostic groups represented within the synthesis included thirty-four trials addressing fibromyalgia, eight evaluating chronic low back pain, five examining knee osteoarthritis, one investigating myofascial pain, one focusing on neck pain, two studying unspecified musculoskeletal pain conditions, and one trial analyzing low back and neck pain concurrently. Intervention protocols varied across technological approaches: transcranial direct current stimulation protocols employed current intensities ranging from 1 to 2 milliamperes across 1 to 60 treatment sessions lasting 20 to 30 minutes; repetitive transcranial magnetic stimulation studies applied frequencies between 1 and 20 hertz across 3 to 20 sessions delivering 1,000 to 4,000 pulses; cranial electrotherapy stimulation trials administered 0.1 milliampere currents for 60 minutes across 10 to 40 sessions; transcranial pulsed current stimulation used up to 4 milliamperes across eight 30-minute sessions; transcranial alternating current stimulation and transcranial random noise stimulation applied 1 to 1.5 milliamperes across ten sessions; and intermittent theta-burst stimulation delivered 9,000 pulses across four sessions of approximately 10 minutes duration.
Within the primary network meta-analysis evaluating the overall chronic musculoskeletal pain cohort, active interventions demonstrated substantial efficacy over sham controls across individual outcome measures. For pain reduction across forty-five trials evaluating thirteen distinct interventions, low-frequency repetitive transcranial magnetic stimulation targeting the dorsolateral prefrontal cortex yielded a standardized mean difference of minus 1.19 with a ninety-five percent confidence interval spanning minus 1.86 to minus 0.52 across three trials. Cranial electrotherapy stimulation produced a standardized mean difference of minus 1.04 with a confidence interval between minus 1.97 and minus 0.11 across two studies. Transcranial direct current stimulation applied over the primary motor cortex achieved an effect size of minus 0.74 with a confidence interval from minus 1.06 to minus 0.42 across fifteen trials, matching high-frequency repetitive transcranial magnetic stimulation targeting the primary motor cortex, which achieved a standardized mean difference of minus 0.74 and a confidence interval of minus 1.18 to minus 0.30 across eight studies. High-frequency stimulation targeting the dorsolateral prefrontal cortex also significantly reduced pain, showing an effect size of minus 0.51 with a confidence interval of minus 1.00 to minus 0.02 across six studies.
Evaluating psychological comorbidities across the general chronic musculoskeletal pain network revealed distinct patterns of therapeutic responsiveness. In sixteen trials examining anxiety outcomes across eight interventions, transcranial random noise stimulation targeting the primary motor cortex ranked highest, generating a standardized mean difference of minus 1.66 with a ninety-five percent confidence interval of minus 3.05 to minus 0.28 from a single trial, followed by transcranial direct current stimulation over the primary motor cortex with an effect size of minus 0.66 and a confidence interval between minus 1.16 and minus 0.16 across five studies, and low-frequency repetitive transcranial magnetic stimulation over the dorsolateral prefrontal cortex yielding minus 0.66 with an interval of minus 1.26 to minus 0.07 across three studies. In depression analyses encompassing twenty-five trials and eleven interventions, intermittent theta-burst stimulation targeting the dorsolateral prefrontal cortex achieved the top cumulative ranking probability, while low-frequency repetitive transcranial magnetic stimulation targeting the same cortical site demonstrated an effect size of minus 0.63 with a confidence interval from minus 1.00 to minus 0.26 across four studies. Transcranial direct current stimulation over the dorsolateral prefrontal cortex yielded minus 0.58, high-frequency magnetic stimulation over the prefrontal cortex produced minus 0.49, and direct current stimulation over the motor cortex achieved minus 0.38, all showing statistically significant improvements relative to sham procedures.
Given that certain top-ranking interventions in the primary models were informed by sparse trial evidence, the investigators performed sensitivity analyses by excluding modalities supported by fewer than three randomized trials, such as intermittent theta-burst stimulation and transcranial random noise stimulation. Following the removal of sparsely supported interventions, low-frequency repetitive transcranial magnetic stimulation targeting the dorsolateral prefrontal cortex demonstrated the highest cumulative probability of ranking first across all three measured endpoints: pain intensity, anxiety symptoms, and depressive severity. Furthermore, when sensitivity tests altered the assumed correlation coefficient from 0.50 to 0.70 for calculating standard deviations of change scores, low-frequency prefrontal magnetic stimulation emerged as the superior modality for depressive symptom reduction, surpassing alternative modalities. This stability indicates that while techniques like random noise stimulation or theta-burst protocols show strong preliminary effect sizes, their apparent dominance in smaller networks remains vulnerable to trial sample constraints, positioning low-frequency prefrontal magnetic stimulation as the most robust therapeutic candidate across broader symptom clusters.
Subgroup investigations categorized by diagnostic etiology revealed that clinical mechanisms markedly influence therapeutic responses, contrasting fibromyalgia with other chronic pain disorders. In the fibromyalgia subgroup encompassing thirty-four trials, low-frequency repetitive transcranial magnetic stimulation targeting the dorsolateral prefrontal cortex retained the highest ranking for pain relief, demonstrating a standardized mean difference of minus 1.19 with a confidence interval of minus 1.99 to minus 0.39 across three studies, and led rankings for depressive symptoms with an effect size of minus 0.63 and a confidence interval of minus 0.98 to minus 0.27 across four trials. For anxiety in fibromyalgia, initial analysis favored motor cortex random noise stimulation, but sensitivity analyses excluding single-study interventions identified transcranial direct current stimulation targeting the primary motor cortex as the optimal protocol, yielding an effect size of minus 0.97 across three trials. Conversely, in non-fibromyalgia conditions characterized primarily by peripheral tissue damage and localized inflammation—such as knee osteoarthritis and chronic low back pain—cranial electrotherapy stimulation ranked highest for pain alleviation, producing a standardized mean difference of minus 1.39 with a confidence interval of minus 2.41 to minus 0.37, while emotional outcome evidence remained too sparse to permit full network meta-analytic modeling.
Neurobiological mechanisms documented in the literature provide a physiological rationale for these observed clinical distinctions. The dorsolateral prefrontal cortex serves as a critical structural hub responsible for executive cognitive control, emotional processing, and descending inhibitory pain modulation. In persistent pain conditions, this prefrontal region frequently demonstrates diminished tissue volume, disrupted functional activity, and altered connectivity with the default mode network and limbic structures. Low-frequency repetitive transcranial magnetic stimulation applied over the prefrontal cortex is understood to suppress local cortical excitability through long-term depression-like mechanisms, reinforcing descending endogenous analgesic pathways that engage the periaqueductal gray and rostral ventromedial medulla while enhancing cognitive reappraisal of pain sensations. In conditions dominated by central sensitization such as fibromyalgia, prefrontal neuromodulation directly addresses shared neurocircuits governing both sensory distress and mood dysregulation, whereas peripheral inflammatory disorders may respond more favorably to systemic autonomic and neurochemical adjustments, such as alterations in endorphin and cortisol release attributed to cranial electrotherapy stimulation.
The study authors emphasize several critical methodological and clinical limitations that constrain the direct translation of these findings into clinical practice. First, fibromyalgia represented the dominant diagnosis among evaluated cohorts, leaving peripheral musculoskeletal disorders relatively underrepresented and preventing robust network modeling for emotional outcomes outside fibromyalgia. Second, the investigators were compelled to exclude multidimensional outcomes such as sleep quality, functional disability, and overall quality of life due to pronounced instrument heterogeneity and incomplete reporting across original trials. Third, while the network synthesis grouped interventions by modality and anatomical target site, underlying trials exhibited considerable variability in operational stimulation parameters, including electrical intensity, magnetic pulse frequencies, session numbers, and overall therapy duration. Furthermore, the meta-regression indicated that participant age significantly moderated anxiety outcomes—accounting for 28.8 percent of between-study variance—though substantial unexplained residual heterogeneity persisted. Because the primary trials evaluated therapeutic responses immediately upon session completion, the durability and long-term efficacy of non-invasive brain stimulation remain unestablished, underscoring the urgent necessity for standardized, large-scale randomized trials with extended longitudinal follow-up.
Subject of Research: Comparative efficacy of non-invasive brain stimulation modalities for chronic musculoskeletal pain, anxiety, and depression
Article Title: Comparative Efficacy of Non-invasive Brain Stimulation for Pain, Anxiety, and Depression: A Systematic Review and Network Meta-analysis
Article References: Li, Y., Ye, X., Li, S., Xu, J., Wang, H., Pang, L., Li, Y., & Jin, S. (2026). Comparative Efficacy of Non-invasive Brain Stimulation for Pain, Anxiety, and Depression: A Systematic Review and Network Meta-analysis. Pain and Therapy, 15(5), 1281-1311. https://doi.org/10.1007/s40122-026-00860-9
Image Credits: AI Generated
DOI: 10.1007/s40122-026-00860-9
Keywords: non-invasive brain stimulation, network meta-analysis, chronic musculoskeletal pain, fibromyalgia, repetitive transcranial magnetic stimulation, transcranial direct current stimulation, transcranial random noise stimulation, intermittent theta-burst stimulation, cranial electrotherapy stimulation, dorsolateral prefrontal cortex, primary motor cortex, pain management, anxiety symptoms, depressive symptoms, central sensitization, clinical neurostimulation


10 hours ago
8




















English (US) ·
French (CA) ·